Strongbridge Biopharma Net Margin %

Net margin is calculated as Net Income divided by its Revenue. Strongbridge Biopharma's Net Income for the
three
months ended in Mar. 2020 was $-12.70 Mil. Strongbridge Biopharma's Revenue for the
three
months ended in Mar. 2020 was $6.67 Mil. Therefore, Strongbridge Biopharma's net margin for the quarter that ended in Mar. 2020 was -190.26%.

NAS:SBBP's Net Margin % is ranked higher than
50% of the 871
Companies
in the Biotechnology industry.

( Industry Median: -184.68
vs. NAS:SBBP: -181.82
)

Strongbridge Biopharma Net Margin % Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

* Premium members only.

Strongbridge Biopharma Annual Data

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Net Margin %

0.00

0.00

-1,610.60

176.68

-227.76

Strongbridge Biopharma Quarterly Data

Jun15

Sep15

Dec15

Mar16

Jun16

Sep16

Dec16

Mar17

Jun17

Sep17

Dec17

Mar18

Jun18

Sep18

Dec18

Mar19

Jun19

Sep19

Dec19

Mar20

Net Margin %

-424.45

-135.66

-242.61

-160.19

-190.26

Competitive Comparison

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

Strongbridge Biopharma (NAS:SBBP) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Disclaimers: GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC.
Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.